Navigation Links
Revolutionary Device for Premature Ejaculation Treatment
Date:9/6/2012

LONDON, September 6, 2012 /PRNewswire/ --

A newly approved treatment for men experiencing premature ejaculation (PE) was unveiled at the World Congress of Sexual Medicine in Chicago on Monday, the 27th of August 2012.

     (Photo: http://photos.prnewswire.com/prnh/20120906/559405 )

Dr Andy Zamar presented climax control training device and programme Prolong TM, which has been found to prolong the time to ejaculation by an average 11 fold.

The device, to be used in conjunction with the start-stop technique, is: substantially cheaper than current available treatments for PE; free from side effects; provides long-term effects; and requires no prescription or medical consultations.

Prolong TM was developed in 2008, after independent clinical trials in London University Teaching Hospitals in 2004, where the prototype in conjunction with the programme was compared to an active control, the Gold Standard treatment, rather than a placebo. In the trial, 61 per cent of men reported lasting 11 times longer during intercourse after using Prolong, compared to three fold improvements in 40 per cent of men who had undergone Teaching Hospital standard Psychosexual Therapy.

Creator and Harley Street Psychiatrist Dr Zamar said:

"Roughly 30% of men experience premature ejaculation at some point in their lives. While there are a number of current treatments available including Psychosexual Therapy, SSRIs and local anaesthetics, I realised there was a need for an effective, discreet, side effect free and affordable treatment that's easy to access.

"The independent clinical trials have proven the benefits Prolong can make to the lives of men and, subsequently, their partners, so hopefully the availability of the device will mark the beginning of the end to the suffering caused by premature ejaculation."

In light of the clinical trial results, Dr Zamar recommended that Prolong TM should be the first line treatment for PE as well as used alongside other treatments, as the programme has no harmful effects. The presentation was peer reviewed and was published in the August issue of the Journal of Sexual Medicine in the proceedings of the World Meeting on Sexual Medicine 2012.

Prolong TM is an approved treatment for climax control in Europe, available on the Internet at http://www.aboutpe.com and in the UK from April 2012.

Note to Editors:

  • Prolong costs £160 while Psychosexual Therapy costs £600-£800 ($945-$1250/€765-€1025).
  • Based on the expected large effect size of Prolong TM and a study power of 80% (the globally accepted clinical trial standard), it was calculated that 52 participants were to be enrolled in the clinical trial.
  • Comparing the effect sizes of Prolong TM with other effective treatments- Antidepressants have an effect size in the treatment of depression of 0.31, local anaesthetics and antidepressants have an effect size of between three and six in the treatment of PE, whilst Prolong has an effect size of 11 for the treatment of PE, making Prolong TM 2-3.5 times more effective than other treatments for PE.
  • Benefits were noted at week one, were maximal at week six and lasted at least three months after the programme was completed.
  • Prolong is approved in the 31 countries of the European Economic Area, for Climax Control training as a Class II a medical device.


'/>"/>
SOURCE The London Psychiatry Centre
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta to Showcase Revolutionary Agility Beam-shaping Innovation at Radiation Physics Annual Meeting
2. China Health Resource Develops Revolutionary Migraine Medication
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
5. Brazil Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
6. Global Peripheral Vascular Devices Market 2011-2015
7. Nelson Laboratories to Present Latest FDA Trends at MEDevice Forum San Diego
8. Institut Curie Acquires Four Advanced Radiotherapy Treatment Systems Including Three Varian TrueBeam Devices
9. Governor Corbett: Pharmaceutical and Medical Device Packaging Company to Create New Jobs in Lehigh Valley
10. Global Airway Management Devices Industry
11. MarketsandMarkets: Sports Medicine Devices Market is expected to reach $5.7 billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis and Strategies ... Oesophageal Cancer market. The research answers the following questions: ... for Oesophageal Cancer and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... KS (PRWEB) , ... February ... ... StaffBridge sets a new technology standard in staffing, scheduling, and reporting for ... monitor, and predict activity throughout the entire staffing process. StaffBridge technology improves ...
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
Breaking Medicine News(10 mins):